SURGICAL EXPERIENCE IN PEOPLE WITH HEMOPHILIA A OR B WITH AND WITHOUT INHIBITORS RECEIVING FITUSIRAN
Alok-Srivastavaa,b, Pencho-Georgievc, Toshko-Lissitchkovd, M V-Ragnie, Juliana-Aragaof, L A-Menapaceg, Yuqian-Shenh, Marja-Puuruneng, Marek-Demissieg, S W-Pipei
a Department of Haematology, Christian Medical College (CMC), Vellore India
b Centre for Stem Cell Research (CSCR), inStem, Vellore, India
c University Multiprofile Hospital for Active Treatment “Sveti Georgi”and Medical University Plovdiv, Bulgaria
d Clinic Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria
e University of Pittsburgh and Hemophilia Center of Western Pennsylvania (HCWP), Pittsburgh, PA, United States
f Sanofi Medley Farmaceutica Ltda, Suzano, São Paulo, SP, Brazil
g Sanofi, Cambridge, MA, United States
h Sanofi, Bridgewater, NJ, United States
i Departments of Pediatrics and Pathology, University of Michigan (UM), Ann Arbor, MI, United States
Ver másLido
864
Vezesque se leu este artigo
306
Total PDF
558
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 12 | 20 | 11 | 31 |
| 2025 11 | 71 | 45 | 116 |
| 2025 10 | 50 | 36 | 86 |
| 2025 9 | 47 | 21 | 68 |
| 2025 8 | 35 | 26 | 61 |
| 2025 7 | 30 | 15 | 45 |
| 2025 6 | 37 | 22 | 59 |
| 2025 5 | 38 | 16 | 54 |
| 2025 4 | 41 | 11 | 52 |
| 2025 3 | 44 | 10 | 54 |
| 2025 2 | 55 | 11 | 66 |
| 2025 1 | 25 | 19 | 44 |
| 2024 12 | 22 | 18 | 40 |
| 2024 11 | 26 | 22 | 48 |
| 2024 10 | 17 | 23 | 40 |
Mostrar tudo
